1. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis

  2. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

  3. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival

  4. Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis

  5. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors

  6. MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian Carcinoma

  7. MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis

  8. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression

  9. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

  10. Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer

  11. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes

  12. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

Previous

2023
Next

2021